LPA Receptor Antagonists for Fibrosis and Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with lysophosphatidic acid (LPA) receptors lack effective inhibitors to manage conditions such as fibrosis, cancer, and inflammatory diseases, where LPA receptor activation contributes to pathology and symptoms.
Innovation Solution
Development of compounds, specifically those of Formula (I), (II), (III), (IV), (V), and (VI), which act as antagonists to inhibit the physiological activity of LPA receptors, particularly LPA1, LPA2, LPA3, and other LPA receptors, to treat or prevent diseases involving fibrosis, cancer, and inflammatory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LPA receptor antagonists are developed to treat diseases, then therapeutic effectiveness is improved, but drug development complexity increases
Solution Approach 1:
The patent segments the LPA receptor antagonists into multiple series (I-VII) with distinct structural features and selectivity profiles. Each series targets specific LPA receptor subtypes (LPA1, LPA2, LPA3, LPA4, LPA5, LPA6) with varying degrees of selectivity, allowing tailored therapeutic approaches for different diseases based on which receptor subtype is most involved in the pathology.
Solution Approach 2:
The patent applies local quality by modifying specific regions of the core chemical structure (indicated by variable substituents R1-R6, R8-R12, and position indicators a-b) to fine-tune receptor selectivity and pharmacological properties. This allows optimization of each compound series for specific therapeutic indications while maintaining the core antagonistic mechanism.
2Adaptability or versatility
If broad-spectrum LPA receptor antagonists are used, then versatility in treating different diseases is improved, but selectivity for specific receptors deteriorates
Solution Approach 1:
The patent creates a dynamic framework where the degree of receptor selectivity can be adjusted by choosing different compound series and structural variants. Researchers can select compounds with broader or narrower selectivity profiles depending on the specific disease indication, allowing the same chemical platform to serve multiple therapeutic purposes with optimized selectivity for each application.
3Object-affected harmful factors
If LPA receptor activation is inhibited, then fibrosis and cancer progression are reduced, but normal cellular functions may be affected
Solution Approach 1:
The patent applies local quality by developing compounds with selective affinity for pathologically overexpressed LPA receptor subtypes in diseased tissues. By targeting specific receptor isoforms that are upregulated in fibrotic or cancerous conditions, the compounds can inhibit harmful LPA signaling in disease states while sparing normal physiological processes that depend on LPA signaling through other receptor subtypes.
Data Source
AI summary
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.